Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.59 |
| ▸ | PARP1 | P09874 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16334671 | 1.00 | USP30 (0.65) | USP30CHRM1PARP1NPC1RAB9A | |
| SCHEMBL10224520 | 1.00 | USP30 (0.65) | USP30CHRM1PARP1NPC1RAB9A | |
| SCHEMBL5145035 | 0.85 | USP30 (0.82) | USP30CHRM1PARP1MEN1KMT2A | |
| SCHEMBL21598915 | 0.82 | USP30 (0.56) | USP30PARP1HDAC4HDAC6 | |
| SCHEMBL269690 | 0.81 | USP30 (0.58) | USP30PARP1MEN1KMT2AHDAC4 | |
| SCHEMBL268538 | 0.81 | USP30 (0.58) | USP30PARP1MEN1KMT2AHDAC4 | |
| SCHEMBL268539 | 0.81 | USP30 (0.58) | USP30PARP1MEN1KMT2AHDAC4 | |
| SCHEMBL12991579 | 0.81 | ALDH1A1 (0.51) | USP30RAB9AMEN1KMT2A | |
| SCHEMBL31451464 | 0.81 | USP30 (0.69) | USP30PARP1HDAC4HDAC6GABRA5 | |
| SCHEMBL22449355 | 0.81 | USP30 (0.69) | USP30PARP1HDAC4HDAC6GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088791-A1 | AMIDOBIPIPERIDINECARBOXYLATE M1 ALLOSTERIC AGONISTS, ANALOGS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010096703-A1 | AMIDOBIPIPERIDINECARBOXYLATE M1 ALLOSTERIC AGONISTS, ANALOGS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088791-A1 | AMIDOBIPIPERIDINECARBOXYLATE M1 ALLOSTERIC AGONISTS, ANALOGS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | CHRM1, CHRM5, CHRM2 | USP30 3305/4885CHRM1 1/4885PARP1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.